Source: Virtual Congress 2020 – Biomarkers and mechanistic aspects of idiopathic pulmonary fibrosis
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
D. Araújo Barros Coelho (Porto, Portugal), C. Sousa (Porto, Portugal), M. Jacob (Porto, Portugal), H. Novais-Bastos (Porto, Portugal), N. Melo (Porto, Portugal), P. Caetano Mota (Porto, Portugal), A. Morais (Porto, Portugal). The role of monocyte count on monitoring patients with Idiopatic Pulmonary Fibrosis  under antifibrotic treatment. 722

Member's Comments

No comment yet.

Related content which might interest you: Impact of an interstitial lung diseases Nurse on the compliance to anti-fibrotic drugs in patients with Idiopathic Pulmonary Fibrosis. Source: International Congress 2018 – Idiopathic interstital pneumonias other than idiopathic pulmonary fibrosis (IPF) Year: 2018 Role of macrophage activation in type II alveolar cells transplantation for the treatment of idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Translational studies in chronic repair and remodelling in the lung Year: 2013 Expression of macrophage migration inhibitory factor in patients with idiopathic pulmonary fibrosis Source: International Congress 2015 – Interstitial lung diseases II Year: 2015 Anti-fibrotic efficacy of nintedanib on pulmonary fibrosis via suppression of fibrocyte activity Source: International Congress 2016 – IPF: from pathogenesis to treatment I Year: 2016 Impaired lung NK activity in the lung of Idiopathic Pulmonary Fibrosis patients Source: Virtual Congress 2021 – Genetics and translational aspects of idiopathic pulmonary fibrosis Year: 2021 Pirfenidone therapy for patients with progressive idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 3 Year: 2014 Pathogenesis of idiopathic pulmonary fibrosis: role of neutrophil inflammation Source: Eur Respir J 2006; 28: Suppl. 50, 102s Year: 2006 Blood monocyte counts as a potential prognostic marker for idiopathic pulmonary fibrosis: analysis from the Australian IPF registry Source: Eur Respir J, 55 (4) 1901855; 10.1183/13993003.01855-2019 Year: 2020 PET-CT with 18F-FDG and 18F-FBEM-labeled leukocytes for metabolic activity and leukocyte recruitment monitoring in a mouse model of pulmonary fibrosis Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 Anti-fibrotic drugs differently affect inflammatory and redox status in bronchial epithelial cells from Idiopathic Pulmonary Fibrosis patients Source: International Congress 2019 – Extracellular matrix formation and remodelling in physiology and disease Year: 2019 Assessment of blood biomarkers in patients with IPF under antifibrotic therapy Source: International Congress 2018 – Back to basics and translational research in idiopathic interstitial pneumonias Year: 2018 Long-term survival analysis: Pirfenidone compared to standard care for the treatment of patients with idiopathic pulmonary fibrosis Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Clinical profile and early follow-up of patients receiving pirfenidone in the PIONEER observational study Source: International Congress 2014 – ILDs 6 Year: 2014 Conduct of a biomarker study in bronchiectasis patients: Correlation of neutrophil elastase activity and inflammatory load in induced sputum Source: International Congress 2014 – Systemic and airway biomarkers Year: 2014 Long term efficacy of pirfenidone therapy in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2014 – ILDs 3 Year: 2014 M2 macrophages derived from patients with idiopathic pulmonary arterial hypertension are susceptible for apelin-mediated suppression of pro-inflammatory cytokines Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 Platelet activation indices in patients with Idiopathic Pulmonary Fibrosis Source: International Congress 2014 – ILDs 5 Year: 2014 Significant changes in monocyte subsets during infliximab therapy in severe sarcoidosis Source: International Congress 2015 – Sarcoidosis: pathogenesis Year: 2015 Effect of pirfenidone on TGF-beta-induced pro-fibrotic effects in primary human lung cells derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 2 Year: 2014 Sildenafil inhibit dose-dependently profibrotic and remodelling effects of TGFbeta1 on pulmonary arteries from patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014